Jan 6, 2023 02:05PM
Dec 22, 2022 06:45PM
Nov 29, 2022 08:33PM
Nov 29, 2022 07:50PM
Nov 29, 2022 07:50PM
Nov 20, 2022 08:50PM
Nov 20, 2022 06:30PM EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFEREN
Sep 28, 2022 07:00AM
Sep 28, 2022 01:15AM
Sep 27, 2022 07:30PM
Aug 3, 2022 07:32PM
Aug 3, 2022 07:25PM
Jul 25, 2022 07:32PM
Jul 25, 2022 07:04PM Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
Jul 5, 2022 08:12PM
Jul 5, 2022 07:30PM
May 9, 2022 09:23PM
May 9, 2022 07:31PM
Sep 27, 2021 09:37PM
Sep 27, 2021 07:30PM
May 6, 2021 09:08PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
Dec 10, 2020 07:43PM
Jul 9, 2020 06:16AM
Jul 8, 2020 10:11PM
Sep 27, 2019 01:24PM
Sep 19, 2019 12:35PM
Jun 11, 2019 11:00AM
Jun 11, 2019 08:00AM Extensive Analyses of Phase 3 Data for Investigational Lemborexant Assess Efficacy and Safety Profile for the Potential Treatment of Insomnia in Adults
Apr 30, 2019 08:27PM
Apr 30, 2019 07:09PM
Apr 24, 2019 10:06AM
Mar 11, 2019 06:43PM
Mar 11, 2019 08:01AM
May 30, 2018 11:33PM
May 24, 2018 09:43PM Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib
May 24, 2018 07:34PM
Sep 29, 2015 02:09AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All